chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Fever 100.4; chills; muscle aches; nausea; tired; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old-non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 04May2021 at 11:00 (at the age of 25-year-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy and gluten sensitivity. The patient did not receive any concomitant medications within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on an unknown date, as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 04May2021, the patient underwent PCR test and the result was unknown. The patient was not diagnosed with COVID-19 prior to the vaccination. Since the vaccination, the patient had been tested for COVID-19. On 05May2021, the patient underwent temperature check and the result was 100.4 with unspecified units. On 05May2021 at 00:00, the patient experienced fever 100.4, chills, muscle aches, nausea and tiredness. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events of fever, chills, muscle aches, nausea and tiredness was not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.  Amendment: This follow-up report is being submitted to amend previously reported information: Lab data (result updated for Body temperature as 100.4), Event details (Treatment received selected as No for all events), updated narrative (The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events).
Malaise in the evening and woke up with chills, the next day had malaise and achy and significant soreness of arm three days following
Redness at injection site; Tenderness at injection site; Might have gotten the vaccine subcutaneously; Itching at the injection site; Hard injection site; A spontaneous report w was received from a nurse concerning herself, a 66-year-old, female patient who received Moderna's COVID-19 Vaccine (mRNA-1273) and might have received the vaccine subcutaneously and experienced itching at the injection site itching, redness, a hard injection site and tenderness at the injection site.  The patient's medical history included an allergy (unknown) and high blood pressure. Concomitant medications included cetirizine, famotidine, losartan, folic acid, calcium, ascorbic acid, and cyanocobalamin.   On 02-Jan-2021, a few hours prior to the onset of the symptoms, the patient received the first of two planned doses of mRNA-1273 (Lot 025L20A) intramuscularly in the left arm for prophylaxis of COVID-19 infection.   A few hours after receiving the vaccine, the patient started to feel itching at the injection site. Later that same night, she developed redness and the injection site became hard and a little tender. The following day the reaction was worse and lasted for four days By 06-Jan-2021 the reaction was gone but appeared again and lasted until 11-Jan-2021. She also mentioned that the needle used for the injection was 25-gauge needle so she believed she may have received the vaccine subcutaneously.   Treatment for the events included hydrocortisone cream.    Action taken with mRNA-1273 in response to the event was not provided.   The outcomes of the event, might have received the vaccine subcutaneously, was resolved on 02 Jan 2021. The events, itching at the injection site itching, redness, a hard injection site and tenderness at the injection site, were considered resolved on 11 Jan 2021.; Reporter's Comments: This case concerns a 66-year-old, female patient, with history of allergy and hypertension, who experienced a non-serious unexpected event of incorrect route of product administration, injection site pruritus, injection site induration, non-serious expected events of, injection site erythema and injection site pain. There was no AEs associated with incorrect route of product administration. The events of, injection site pruritus, injection site induration, injection site erythema, and injection site pain, occurred 1 day (same day) after first dose of mRNA-1273, lot # 025L20A. Treatment included cortisone cream. Based on the current available information and temporal association between the use of the product and onset of the events (injection site pruritus, injection site induration, injection site erythema, injection site pain), a causal relationship cannot be excluded.
5 days 1/5/18 after receiving injection, I felt my pointer finger on right hand become tender, by 1/8/2018 my right hand was throbbing, swollen, red, and very hot. I have had gout before only on my toe so knew this was gout.
Patient received Subcutaneous dose of ZOSTAVAX 5/26/09. Patient returned to pharmacy 5/29/09 with questions about localized reaction to injection. Site was red, slightly raised, about 2" diameter. No pain, no itching.
Enlarge lymph node on the left neck area underneath the collarbone.  Left arm had a tingling sensation.  Unable to walk on left foot due to swelling.
Less than recommended dose level vaccine was adminbsitered; This spontaneous case was reported by a consumer and describes the occurrence of ACCIDENTAL UNDERDOSE (Less than recommended dose level vaccine was adminbsitered) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 14-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-May-2021, the patient experienced ACCIDENTAL UNDERDOSE (Less than recommended dose level vaccine was adminbsitered). At the time of the report, ACCIDENTAL UNDERDOSE (Less than recommended dose level vaccine was adminbsitered) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
4th Rabies vaccine administered at 1615. Pt. c/o ringing in (R) ear with 50% hearing loss after 7 minutes. Provider to room to examine. VSS with no significant change from baseline. Pt. denied any other symptoms.
New onset rash of abdomen and back. States rash is very itchy but denies pain or fever.  Rash coincides with administration of Tdap 8/12/2019. Pt without rash at site of injection but with ongoing mild discomfort at injection site. No rash at site where silver sulfadiazine applied.  Zyrtec 10mg PO BID x 1-2 days  red flags reviewed for urgent f/u- SOB, tongue or lip swelling
Constant confusion. Depression is worse. On my left arm in the fold of the elbow I have blocked veins. I have body twitches or muscle twitches. I am tense all the time. Neck and left arm hurt. Became allergic to tattoo ink. Left side of my body tingles, face, arm, leg. Chest pain. Left arm goes numb if I lift it.
Itching and a red raised blister appeared after two months of getting vaccine administered, pt. has mild pain and soreness.
Moderate rash on head,back of thigh, buttocks. Minor rash on palms of hand
At approximately, 9:40 am I administered the Moderna Covid-19 vaccine with lot number: 020B21A with the expiration date 09/23/21 to a female patient. Approximately, 10 mins. into her waiting period the patient told me that she's experiencing rash which I witnessed on her chest area. At that time, I  asked did she have any difficulty breathing, tingling sensations around the face area, and any swelling of the face and tongue. She told me she was negative of the symptoms stated besides the rash. At approximately, 10:05 a.m. I gave the patient 10 mLs of liquid Benadry for a dose of 25 mg and I instructed the patient to wait another 5 to 10 minutes to see if symptoms persists and/or discontinue. I monitored the patient for an additional 15 mins and at that time I asked the patient how she's doing and she stated that  "the rash now traveled down to her legs". At that time I told the patient that I for your safety I'll have to administer a Epi-Pen injection. At that time, I let the store manager know of my intentions, instructed my technician to call 911, and administered one dose of the injection. I remained with the patient until EMS arrived at the scene.  According the patient she's had prior mild allergic reactions before, but nothing as serious as Penicillin. Overall, she seemed nervous during this time but was very understanding, calm and thankful that I remained with her.
PT was 11 years and 10 months old.  12 year dose was given in error.  No adverse effects reported by PT's mother.
This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Vaccination adverse reaction) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The patient's past medical history included Kidney transplant. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Vaccination adverse reaction). At the time of the report, VACCINATION COMPLICATION (Vaccination adverse reaction) outcome was unknown. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available). On an unknown date, SARS-CoV-2 antibody test: negative (Negative) Negative. No relevant concomitant medications were reported. No treatment information was provided.
RECIEVED VACCINE11/15/2021.MY LEFT ARM BECAME VERY SWOLLEN AND FEVERISH.THE SWELLING SORENESS AND FEVER CONTINUED UNTIL NOV.24 AS THE SWELLING STARTED TO GO DOWN I GOT A VERY HIGH TEMPATURE AD BECAME VERY SICK. i WAD ADMITTED TO THE HOSPITAL FOR 5 DAYS. i AM STILL NOT BACK TO BEING MY NORMAL SELF. i AM VERY FATIGUED .
Inject site reaction, swelling all upper arm aside from injection site, down inside of left arm. Pt. gave ice therapy. Red, swollen and pt had fever, took TYLENOL. After 3 days was better although not entirely gone.
This spontaneous report was received from a medical assistant concerning an unknown number of patients of unknown age and gender. The patients' medical history, concurrent conditions and concomitant medications were not reported. On unknown dates, the patients were vaccinated with doses of RECOMBIVAX HB, for prophylaxis (dose number, route, lot # and expiration date were unknown), which were improperly stored at 1 Celsius degree for 17 minutes. There was no previous temperature excursion. A digital data logger was involved. No adverse symptoms were reported. This is one of several reports received from the same reporter. Additional information has been requested.; Sender's Comments: US-009507513-1704USA013334: US-009507513-1704USA013570: US-009507513-1704USA013572:
So at the spot of injection it was swollen. The next day my hand began bleeding, I suspected clotting. After a few days, I experienced tingling in my hip and it progressed down my leg as the days went by. By January, I began seeing the doctor, and by April the tingling did not stop and I now started to get tremors. At this point, I was diagnosed with anemia. I was referred to a hematologist. That doctor said that the blood pattern looked like lupus. I went back to my primary and was scheduled for rheumatologist.  I was diagnosed with Lupus about a week ago, 6/2022. I am seeing a rheumatologist soon as a follow up. I have not have Covid and if I ever did then I was A symptomatic.
This spontaneous case reported by a consumer, describes the occurrence of asthenopia (tired eyes), vaccination site pain (sore injection arm), vaccination site rash (red rash at the injection site) and nausea (little nauseous) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 vaccine, batch/lot# 011M20A) for COVID-19 immunization. No medical history reported. On Feb 15, 2021, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), unknown route; 1 dosage form. February 2021, patient experienced asthenopia (tired eyes), vaccination site pain (sore injection arm), vaccination site rash (red rash at the injection site) and nausea (little nauseous). In February 2021, asthenopia (tired eyes), vaccination site pain (sore injection arm), vaccination site rash (red rash at the injection site) resolved. At the time of the report, nausea (little nauseous) resolved. The action taken with mRNA-1273 (Moderna COVID-19 vaccine): unknown. No concomitant medication or treatment information provided. This case  linked to MOD-2021-398849 (patient link).
The first week following the vax, the pt experienced general malaise, rash, fever, the 2nd week, the pt experienced general malaise, and joint aches.
The day of the vaccine I was very tired. The next day I had muscle pain, 100 degree fever and my skin felt very sensitive. light touch caused small amount of pain at surface level
Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 10-FEB-2022; Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 10-FEB-2022; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 10-FEB-2022) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 10-FEB-2022) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066H21A) for COVID-19 vaccination.     It was unknown if patient had acute illnesses and chronic and long standing health conditions.     On 10-Feb-2022 at 1:36 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 10-Feb-2022 at 1:36 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 10-FEB-2022). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 10-FEB-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 10-FEB-2022) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 10-FEB-2022) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant products were reported.  This vaccine was administered up until its manufacturing expiry date of 04-Apr-2022. The patient received the booster dose.  No treatment medications were provided.   This case was linked to MOD-2022-542869.
VACCINATION WITH JANSSEN COVID19 VACCINE WHO HAD ALREADY RECEIVED FIRST DOSE OF MODERNA COVID19 VACCINE; This spontaneous report received from a pharmacist concerned a female of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient was previously treated with mrna 1273 for prophylactic vaccination. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 27-MAY-2021 15:00 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 27-MAY-2021, the subject experienced vaccination with janssen covid19 vaccine who had already received first dose of moderna covid19 vaccine. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of vaccination with janssen covid19 vaccine who had already received first dose of moderna covid19 vaccine was not reported. This report was non-serious.
Flu like symptoms- started with fatigue, then chills slightly elevated. Temp, nausea, joint pain, aches, not much of an appetite but still ate.  Tylenol and Benadryl took care of it fairly well.  Had arm pain at site of injection, like I was hit in arm with a baseball bat.  Had some gerd too but not sure if related. Tiredness started around 9 hours after the shot, but symptoms really kicked in about 12 hours after administration.  Lasted till about 46 hours after administration, at which time I woke up from overnight sleep feeling great.  Arm still sore and there might be some lingering joint pain but nothing to keep me from doing anything.
After about 45 min of vaccine, pt reportedly had a itchy rash and swelling of lips. Rash was on body and face. Pt felt dizzy. Taken to hosp in private car and pt fainted (syncope) at hosp parking lot. Evaluated at the ED at hosp. In ED exam normal - (no rash).
Chills; slight fever; This spontaneous case was reported by a consumer and describes the occurrence of CHILLS (Chills) and PYREXIA (slight fever) in an 89-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 001821A and 041L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 31-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced CHILLS (Chills) and PYREXIA (slight fever). At the time of the report, CHILLS (Chills) and PYREXIA (slight fever) outcome was unknown.            Concomitant medications were not reported. Treatment details not provided. The patient had queried about information about the contamination of Moderna COVID-19 vaccine vials, about the third dose and comparisons with a booster of the Pfizer COVID-19 vaccine and why the Moderna COVID-19 vaccine has not been approved yet in the country.   Most recent FOLLOW-UP information incorporated above includes: On 31-Aug-2021: significant Follow up: updated narrative
Client received Moderna first dose, then Pfizer second dose. Client was scheduled for Moderna, but received Pfizer in error.
"Woke up with a fever subjective treated with Ibuprofen, stayed from school today. This afternoon temp was 100 degrees F and arm was red and swollen. 2 hrs ago noticed there were blisters; subjectively not feeling well but eating okay. This AM mentioned throat hurt. Symptoms include no abdominal pain, no anorexia, no cough, fever, generalized myalgias, no nasal dic, no nausea, sore throat, and no vomiting".
New onset of nose bleed in left nostril causing 2 er visits, one urgent care visit and an ENT visit for cauterization
A report has been received from a Health Professional concerning a 6 year old, subject of unknown gender, who had been receiving Nasal FLUMIST Quadrivalent (Intranasal), 0.2 Millilitres. FLUMIST Quadrivalent (Intranasal) started on 03-Mar-2016. It was reported that FLUMIST which expired on 02-MAR-2016 was given to the patient on 03-Mar-2016 it was administered by the patient and which was considered as an off label use. The outcome of the event of given expired dose - off label use and administration of expired dose is unknown. The report was considered to be non-serious.
Hives, Red rash on under arms, inside of legs, stomach and chest.  Still happens as of today.
low grade fever/103° fever; chills; muscle aches; was exposed; dull headache; congestion; eyeballs hurt; rash; leg is active at night; feeling dizzy and fuzzy "like I've been drinking kind of thing."; feeling dizzy and fuzzy "like I've been drinking kind of thing."; feeling dizzy and fuzzy "like I've been drinking kind of thing."; This is a spontaneous report from a contactable consumer (patient). A 40-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Formulation: Solution for injection, Lot number and expiration date was not reported) via an unspecified route of administration on 09Aug2021 as dose 1, single for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient experienced low grade fever/103 degree fever, chills and muscle aches on 11Aug2021, was exposed (exposure to sars-cov-2), dull headache, congestion, eyeballs hurt, rash, leg is active at night, feeling dizzy and fuzzy "like i've been drinking kind of thing" on an unspecified date in Aug2021. It was reported that, she was exposed prior to getting the vaccine and wasn't aware of it if she got COVID before the shot or 5 days after the first dose and wanted to know if patients with previous exposure to COVID-19 infection could still take the second shot. She was not sure if she had side effects from the vaccine or COVID-19. Patient wanted to know how long did these side effects last. Patient stated that, as of today 13Aug2021 she still had dull headache, low grade fever, congestion and her eyeballs hurt. She also had a rash and her leg was active at night. She was feeling dizzy and fuzzy like she had been drunk kind of thing. Caller also stated that for 2 days after the vaccine she had 103 degree fever, chills, muscle aches for 2 days. Headache had not gone away and seems like everything was kind a lingering. She wanted to know if it was typical for 1% of people to experience the side effects for a week. The patient underwent lab tests and procedures which included pyrexia: 103 degree on an unspecified date. The outcome of the events low grade fever/103 degree fever, chills and muscle aches was recovered on an unspecified date, dull headache was not recovered and for events was exposed, congestion, eyeballs hurt, rash, leg is active at night and feeling dizzy and fuzzy "like i've been drinking kind of thing." it was unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
7 year old given a .3ml (dose for 12+) according to medical chart. No reaction as of yet. Was informed by health department to file a report.
soreness at injection site; rash at injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE RASH (rash at injection site) and VACCINATION SITE PAIN (soreness at injection site) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Jan-2021, the patient experienced VACCINATION SITE RASH (rash at injection site). On an unknown date, the patient experienced VACCINATION SITE PAIN (soreness at injection site). At the time of the report, VACCINATION SITE RASH (rash at injection site) and VACCINATION SITE PAIN (soreness at injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported.  No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 18-Apr-2021: Follow up received on 18-Apr-2021 with no new information and patient not interested in Follow up.